MAZE Maze Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why MAZE matters now
Maze Therapeutics, Inc. (MAZE) is a US stock in Healthcare. The latest InvestLog snapshot shows $30.57 with -5.71% on the session and $1.69B in market capitalization; recent performance reads 1-month +4.99% and YTD -38.02%.
The latest financial table shown here is Q1 2026, with revenue of $20.0M, net income of $-24.2M, and EPS of $-0.45. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.6%.
The latest indexable market news headline is "What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $64.00; recent insider activity includes Andrews Nancy C filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.05
P/S
71.06
EV/EBITDA
-10.74
DCF Value
$3.82
FCF Yield
-8.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.0%
Operating Margin
-670.3%
Net Margin
-612.7%
ROE
-36.6%
ROA
-29.2%
ROIC
-33.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.0M | $-24.2M | $-0.45 |
| Q4 2025 | $0.00 | $-34.6M | $-0.87 |
| FY 2025 | $0.00 | $-131.1M | $-3.05 |
| Q3 2025 | $0.00 | $-30.1M | $-0.66 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$69.00
Target (Median)
$64.00
Target Range
$46.00 - $97.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.26
Maze Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the creation of precise small molecule medications for a range of ailments within the United States. Its primary therapeutic targets encompass renal, cardiovascular, and associated metabolic conditions, alongside obesity. The company's developmental pipeline highlights two leading drug candidates: MZE829, an oral small molecule engineered to inhibit apolipoprotein L1, which is currently in Phase II clinical studies for APOL1 kidney disease; and MZE782, another oral small molecule designed to block the solute transporter SLC6A19, presently in Phase I clinical evaluation for chronic kidney disease. The company, originally incorporated in 2017, adopted its current name, Maze Therapeutics, Inc., in September 2018, having previously been known as Modulus Therapeutics, Inc. It maintains its headquarters in South San Francisco, California.